Medical News

Very High Coronary Artery Calcium (CAC ≥ 1000) and Associati...
Circulation.

Individuals with very high CAC (≥1000) are a unique population at substantially higher risk for CVD events, non-CVD...

03 Mar 2021

Adherence to Antihypertensive Medication and Incident Cardio...
Hypertension.

In conclusion, among young adults who initiated pharmacological treatment for high blood pressure, poor medication...

02 Mar 2021

Ten-Year Outcomes of Percutaneous Coronary Intervention vers...
Diabetes Ther.

During a long-term follow-up time period of 10 years, PCI was associated with worse clinical outcomes compared to...

01 Mar 2021

Gender Differences in the Prevalence of Frailty in Heart Fai...
Int J Cardiol.

In HF, frailty affects women significantly more than men. Future work should focus on elucidating potential causes...

01 Mar 2021

Key Trials

ALLHAT Study: Worsening of Kidney Function-A Major Contributor of HF Risk in Hypertensives

Worsening of kidney function is a major contributor towards the risk of HF in patients with hypertension. Choosing an antihypertensive that would...

Sacubitril/Valsartan Treatment in Patients with HFrEF with and without Diabetes-Impact on Reverse Cardiac Remodeling

This post hoc analysis of PROVE-HF study demonstrated benefits of sacubitril/valsartan in terms of reverse cardiac remodelling and improved NT-...

PROVE HF: Impact of Sacubitril/Valsartan Initiation on Health Status in Patients with HFrEF

This secondary analysis of the PROVE HF trial demonstrated that initiation of sacubitril/valsartan treatment in HFrEF patients was associated with a...

PIONEER-HF: Efficacy and Safety of Sacubitril/Valsartan in ADHF Patients as per the Dose Level Achieved

Sacubitril/valsartan exhibited generally consistent efficacy and safety across various dose levels in hemodynamically stabilized patients with ADHF...

Slide Library

Medical Management Strategy of CTEPH: Role of Riociguat

Riociguat, a stimulator of soluble guanylate cyclase, has been globally approved for the treatment of PAH and inoperable CTEPH and persistent/...

 
Email this page
Macitentan: 1st ERA Proven to Reduce Morbidity and Mortality in PAH

Macitentan is an orally active, potent, tissue targeting ERA that is indicated for the treatment of pulmonary arterial hypertension (PAH). It is the...

 
Email this page
Chronic Thromboembolic Pulmonary Hypertension

Chronic thromboembolic pulmonary hypertension (CTEPH) is the presence of mean pulmonary artery pressure (mPAP) ≥ 25 mmHg following an episode of...

 
Email this page
Diabetic Dyslipidemia

Dyslipidemia is one of the key risk factors for cardiovascular disease (CVD) in diabetes mellitus. This slide set provides information on the...

 
Email this page

Our Publications

Rivazest (Rivaroxaban) Monograph

Rivaroxaban is a potent, selective, orally active direct inhibitor of the activated serine protease Factor X (FXa), which plays a central role in...

Telyse (Tenecteplase) Monograph

In the management of STEMI in India, pharmacoinvasive strategy involving thrombolytics is the preferred therapy in cases of delays in primary PCI....

Mexiletine FAQ Booklet

Mexiletine is a class 1B antiarrhythmic agent, which blocks the sodium channels and is indicated in suppression of ventricular arrhythmias. The...

Mexohar (Mexiletine) Monograph

About 5% of patients with cardiac arrhythmias or with heart failure are diagnosed with a ventricular tachycardia. Recurrent Ventricular Tachycardia...

Patient Education

Understanding Angioplasty

Angioplasty is a life-saving procedure to open up blocked or narrowed blood vessels. This document gives a brief idea about the procedure.

Understanding Obesity

This document explains what is obesity, what is the impact of obesity on overall health and what are the benefits of weight loss. 

Hypertension

Know more about the risk factors, associated ill-effects and tips for management of hypertension or high blood pressure. 

Poll

What percent of your patients who need oral anticoagulation, receive warfarin?
<20%
26% (6 votes)
20-40%
22% (5 votes)
40-50%
13% (3 votes)
50-70%
13% (3 votes)
70-80%
22% (5 votes)
Almost all
4% (1 vote)
Total votes: 23